Introduction
============

Cervical carcinoma is the second most commonly diagnosed cancer and the third leading cause of cancer-related deaths among women in less developed countries [@B1]. Primary vaginal carcinoma is considered one of the rarest of malignant lesions, accounting for approximately 2% of all gynecologic malignancies.

Female genital tract congenital malformations are defined as congenital variations of the normal female anatomy resulting from aberrant embryonic development. They represent a common benign condition with a prevalence of 4-7% and an incidence of 0.2-0.4% in the general population [@B2]. Genital and urinary tract developmental anomalies often occur simultaneously owing to the common embryologic origin of these two organ systems. Approximately 20% of women with genital tract malformations have urinary tract developmental anomalies [@B3], [@B4]. While carcinomas of the lower genital tract and genitourinary malformations are relatively common, their coexistence is rarely reported.

Considering the high incidence of cervical carcinoma worldwide, the absolute number of cervical carcinomas in patients with genitourinary malformation might be expected to be very high, especially in less developed regions. However, the opposite is true, as the number of reported cases is low [@B5]. This may be because the incidence of cervical carcinoma in developed countries is very low; moreover, many less developed regions are less likely to be able to afford imaging prior to surgery or radiotherapy, resulting in a missed diagnose of genitourinary malformations. The majority of patients with malformations from the developing world may also go unreported even if they are detected. Most cases that have been reported were described in case reports. Therefore, the general clinical presentations, pathologic features, and outcomes of lower genital tract carcinoma in patients with genitourinary malformation remain unknown.

We performed a retrospective review of all patients with carcinoma of the lower genital tract and genitourinary malformation who were treated at a single tertiary hospital, and performed a comprehensive literature review. Our goal was to identify the clinicopathologic characteristics and outcomes of these patients, and to analyze the associations among clinicopathologic features in this rare entity.

Methods
=======

Patients
--------

The medical records of patients with carcinoma of the lower genital tract (i.e., the cervix, vagina, and vulva) and genital tract malformations (with or without congenital malformations of the urinary tract) who were treated at Peking Union Medical College Hospital (Beijing, China) between January 1995 and December 2017 were retrieved from the institutional database. All patients were required to have pathologically confirmed cervical and/or vaginal carcinoma on a central review by a gynecologic pathologist at our hospital. The diagnoses of genitourinary malformations were based on physical examination, surgical findings, intravenous urography, ultrasonography, computed tomography, and magnetic resonance imaging (MRI). Medical records were reviewed, and demographic, pathological, and treatment data, and vital statistics were extracted.

Literature review
-----------------

We performed a diligent and comprehensive PubMed search for all studies published between January 1965 and December 2017 using the search terms "genitourinary malformations", "female genital tract anomalies", "renal agenesis", "Müllerian duct anomalies", "uterus didelphys" in combination with either "carcinoma of the cervix", "carcinoma of the vagina" or "carcinoma of the vulva". Additional articles were identified by cross-referencing.

Statistics
----------

The presentations, treatments, and outcomes were summarized using descriptive statistics. The correlations between two variables were explored using Fisher\'s exact test. Quantitative variables were compared using Student\'s t-test. Survival curves were plotted using the Kaplan-Meier method and compared using the log-rank test. All statistical analyses were conducted using the SPSS software for Windows, version 20.0 (IBM Corporation, Armonk, NY, USA). A *P*-value \< 0.05 was considered statistically significant.

Results
=======

Thirty-six female patients with carcinoma and congenital malformations of the genital tract were identified, including 12 from our institution and 24 from the literature [@B6]-[@B26]. Clinicopathologic features, treatments, and outcomes for patients treated at our institution are shown in **Table [1](#T1){ref-type="table"}**, and those of patients previously from the literature are shown in **Table [2](#T2){ref-type="table"}**.

Clinicopathologic features
--------------------------

The average patient age was 39.1 years (range, 20-69). None of the patients had a history of prenatal diethylstilbestrol (DES) exposure. The presenting symptoms for patients with available data are shown in **Table [3](#T3){ref-type="table"}**; the intermenstrual vaginal bleeding durations experienced by 17 patients ranged from one week to five years. Of the 36 patients, 22 had cervical carcinoma, 10 presented with vaginal adenocarcinoma, two presented with carcinoma of both the cervix and vagina with the primary carcinoma site difficult to distinguish, and two had carcinoma of the cervix and vaginal septum. Human papillomavirus (HPV) testing results were available for eight patients; six were negative while two with SCC of the cervix were positive for HPV 16 (patients 11 and 12).

As most of the patients were documented before 2013, the European Society of Human Reproduction and Embryology/European Society for Gynecological Endoscopy classification [@B2] was not applied to female genital tract congenital anomalies. Therefore, we described the malformations as they appeared in the medical records and the literature. The most common genital tract anomalies were uterus didelphys (n=17) and double cervix (n=12). A representative MRI of a patient treated at our hospital is shown in **Figure [1](#F1){ref-type="fig"}A** (patient 8). This patient had complex female genitourinary anomalies which account for \<1% of all genital malformation in adults [@B27], including double cervix, double vagina, lower vagina atresia, congenital vagino-vesical fistula, and cloacal anomalies (imperforate anus). Uterine cervical tumors were detected on her two cervices; these also involved the mucosa of the bladder and rectum. Eight patients (22.2%) had with Herlyn-Werner-Wunderlich syndrome (HWWS), which is also known as obstructed hemivagina and ipsilateral renal anomaly (OHVIRA), characterized by uterine didelphys, obstructed hemivagina, and ipsilateral renal agenesis. Gross specimens of the uterine and both adnexa from the patient with HWWS (patient 6) are shown in **Figure [1](#F1){ref-type="fig"}B.** Among the 20 patients with double cervices (including eight with HWWS), nine had carcinoma on one cervix, eight had carcinomas on two cervices, and three had no carcinoma of the cervix but had carcinoma of the vagina. Twenty-three patients (63.9%) had with urinary tract malformation, including unilateral renal agenesis (URA) (n=21), multiple renal cysts (n=1) and vagino-vesical fistula (n=1). It is notable that patient 2, who was treated at our institution and had right renal agenesis and uterus didelphys, developed multiple primary malignant tumors. She was diagnosed with renal clear cell carcinoma and underwent left heminephrectomy in March 2010, and then, she was diagnosed with mucinous carcinoma of the breast in January 2015 and with vaginal adenocarcinoma in June 2015.

The International Federation of Gynecology and Obstetrics (FIGO) stages of 25 patients with cervical carcinomas are shown in **Table [3](#T3){ref-type="table"}**; an additional patient was diagnosed with carcinoma in situ. Also shown are the FIGO stages of 10 patients with vaginal carcinoma. Of all 36 patients, 25 (69.4%) had adenocarcinoma (including 10 adenocarcinoma, 11 clear cell adenocarcinoma, three endometrioid adenocarcinoma, and one mesonephric adenocarcinoma), 10 (27.8%) had SCC, and one (2.8%) had adenosquamous carcinoma (ASC). All carcinomas of the vagina or vaginal septum were adenocarcinomas. Among the 26 patients with cervical carcinoma, 10 (38.5%) had SCC, one (3.8%) had ASC, and 15 (61.5%) had adenocarcinoma. Among the 25 with cervical and/or vaginal adenocarcinoma, 10 (40%) had clear cell adenocarcinoma and three (12%) had endometrioid adenocarcinoma. The clinicopathologic features of the 36 patients are summarized in **Table [3](#T3){ref-type="table"}**. The representative microscopic images of clear cell adenocarcinoma of the vagina (patient 2) and cervix (patient 8) are shown in **Figure [1](#F1){ref-type="fig"}C** and**1D**, respectively.

Correlation between clinicopathological variables
-------------------------------------------------

The potential correlations between clinicopathological parameters were examined (**Table [4](#T4){ref-type="table"}**). The average age of patients with SCC was 47.0 years, and that of patients with adenocarcinoma or ASC was 36.1 years (*P*=0.011). Of the 23 patients with urinary tract malformation, 95.7% (22/23) were diagnosed with adenocarcinoma (n=21) or ASC (n=1). Of the 13 patients without urinary tract malformations, four (30.8%) were diagnosed with adenocarcinoma. Patients with urinary tract malformations presented with adenocarcinoma significantly more frequently than those without such malformations (*P*\<0.001). Additionally, 15 of 26 patients with adenocarcinoma (57.7%) had FIGO stage II-IV, while the tumor of one patient with SCC (10%) was within that range. Patients with adenocarcinoma had a higher probability of presenting with advanced FIGO stage than those with SCC (*P*=0.022). Notably, all 12 cases of SCC involved the cervix, while 14 of the 24 adenocarcinomas (58.3%) involved the vagina with or without cervical involvement (*P*=0.003). Taken together, patients with SCC of the lower genital tract who had genitourinary malformations were older and had earlier stage disease than patients with adenocarcinoma. Compared to patients without urinary tract malformations, those with such malformation may have a predilection for adenocarcinoma of the lower genital tract.

Treatments and outcomes
-----------------------

As the sites of carcinoma and stages of disease varied among the patients, their treatment modalities differed significantly. Eleven patients underwent surgery alone, 11 underwent surgery followed by adjuvant radiotherapy or chemotherapy, eight underwent radiotherapy or concomitant chemoradiotherapy, and six underwent radiotherapy (two combined with chemotherapy) followed by surgery. Of the six patients who underwent radiotherapy followed by surgery, two with stage IV disease showed viable carcinoma tissue even after radiotherapy and chemotherapy, therefore, pelvic exenteration was performed in these patients. Pathologic results revealed that all six patients who underwent radiotherapy and surgery had residual carcinoma in their surgical specimens even after radiotherapy.

Follow-up information for seven patients from the literature was not available; therefore, we analyzed the outcomes and survival of 29 patients. The median follow-up time was 26 months (range, 2-288 months). Of the 29 patients, four patients died of disease, resulting in a five-year overall survival rate of 80.5%. The 5-year overall survival rate of patients with adenocarcinoma was 75.6% and that of patients with SCC was 100%, although the difference was not statistically significant (*P*=0.279).

Discussion
==========

In this retrospective study and literature review in which we analyzed the characteristics and outcome of 36 patients with genital tract carcinoma and malformations, we found that 63.9% of these patients had simultaneous urinary tract malformations while 69.4% had adenocarcinoma. Moreover, we found that patients with genitourinary tract malformations had a high probability of presenting with adenocarcinoma of the lower genital tract. To our knowledge, our investigation of this rare entity comprises the largest cohort size to date.

The diagnosis of carcinoma of the lower genital tract may be more difficult in women with genital tract malformations than in those without such malformations. First, the clinical presentations of carcinomas in patients with genital malformation may be atypical. Intermenstrual vaginal bleeding is the most common presenting symptom (54.8%) in patients in the present study. Irregular vaginal bleeding is a common symptom of cervical cancer and genital tract malformations in some patients, and it may lead to a delay in the diagnosis or a potential failure to diagnose carcinoma. Additionally, an anatomic abnormality in the genital tract makes gynecological exams difficult to perform, especially for patients with HWWS. Carcinomas located in the obstructed uterine cervix or vaginal wall in patients with HWWS are occult and difficult to detect. Therefore, it is important for these patients to perform rigorous gynecologic examinations and imaging analyses using investigative tools such as colposcopy, hysteroscopy, laparoscopy, hysterosalpingography, ultrasonography, and MRI.

Because the prevalence of genital tract malformations among the general population is estimated to be 4-7% [@B2], it is possible that a similar percentage of women with genital tract cancers may have coexisting malformations. Approximately 15% of carcinomas of the cervix and vagina in the general population are adenocarcinomas. However, in our 36-patient study, adenocarcinoma accounted for a much higher proportion (69.4%). Furthermore, all of the vaginal cancers in our study were adenocarcinomas, which was a significant divergence from the 15% rate in the general population.

Genital and urinary tract developmental anomalies often occur simultaneously owing to the common embryologic origin of these two organ systems. Approximately 20% of women with genital tract malformations have developmental anomalies of the urinary tract [@B3], [@B4]. However, 63.9% of patients with carcinoma and malformations in our study had concomitant urinary tract malformation. Renal anomalies were found in 22 of 36 patients studied (61.1%), with URA being the most common (58.3%). HWWS is a rare variant of Mullerian duct anomalies, which constitute 7.1% of all female genital tract malformations [@B27]. In our study, 22.2% of patients with carcinomas had HWWS, which was higher than the proportion reported by Acién.

With respect to pathological type, the rate of adenocarcinoma was significantly increased when urinary tract malformations were present. Acién and colleagues found that individuals with URA experience endometriosis more often than those who have both kidneys [@B28]. However, they did not find an association between gynecological malignancies and URA. In contrast, our results suggest that genitourinary anomalies are linked to an increased risk of adenocarcinoma, although our sample size was too small to draw definitive conclusions. Consistent with our results, Kusunoki and colleagues reported a case of cervical clear cell carcinoma with OHVIRA syndrome, who had no in-utero DES exposure [@B29].

As to whether patients with congenital genitourinary malformations have a predilection to multiple primary malignant tumors, Woods and colleagues reported a patient with a double vagina, double cervix, uterus didelphys, and URA who had simultaneous uterine endometrial carcinoma and renal cell carcinoma [@B30]. Vale-Fernandes and colleagues described a woman with a single left kidney, a right unicornuate uterus and a rudimentary left horn; she had complex endometrial hyperplasia with atypia, a bulky fibroid of the left ovary, and bilateral fallopian tube in situ serous carcinoma [@B31]. In our study, one patient with right URA and uterus didelphys suffered from renal clear cell carcinoma, breast mucinous carcinoma, and vaginal adenocarcinoma within five years. It is therefore conceivable that such congenital malformations are associated with an increased risk of multiple primary cancers, although the total number of patients examined to date is small and no genetic evidence is available. Determining the genetic background and risk of developing malignancies in patients with genitourinary malformations is warranted.

Approximately 90% of lower genital tract carcinomas are caused by persistent infections with carcinogenic high-risk HPV. However, the development of carcinoma in association with congenital malformations of the genitourinary tract is rare. An extensive search of the English literature, no information was found that specifically addressed the association between or concurrence of these entities. Approximately 75% of patients in our study were negative for HPV, although this statistic was based only on eight patients. It may be interesting to investigate whether high-risk HPV has a role in carcinogenesis in women with congenital genitourinary malformations. The non-viral carcinogenic agents for patients with congenital genitourinary malformations remain unknown.

Based on the link between Müllerian remnants and the development of clear cell carcinoma, Sporri and colleagues, proposed that teratogenic effects may render the Müllerian epithelium sensitive to carcinogenic agents such as DES [@B10]. They posited that the link between teratogenesis and oncogenesis exemplified Knudson\'s two-hit theory of carcinogenesis [@B32]. Carcinogenesis of clear cell carcinoma from Müllerian anomaly is considered, that clear cell carcinoma may have arisen from the paracervix of Müllerian-derived columnar epithelium that have persisted for a long time and was subjected to genetic and hormonal changes [@B29]. Our findings support their hypothesis that the teratogenic effect combined with cancer genetic susceptibility inordinately predisposes patients to the "second hit", resulting in genital tract carcinomas or even multiple primary malignancies.

Given the rarity of genital carcinomas in patients with genitourinary malformations, we were only able to conduct a retrospective study and literature review. Therefore, it was difficult to avoid selection and publication biases. Despite this limitation, however, our study ought to be valuable for understanding this rare entity given our inclusion of the largest sample size hitherto.

Conclusions
===========

We have summarized the features and outcomes of carcinoma of the lower genital tract in patients with genital malformations. Adenocarcinomas were diagnosed at younger ages and more advanced stage in patients with such malformations than in the general population, which led to poorer survival rates. Patients with simultaneous malformations of the genital and urinary tract had a high probability of developing adenocarcinoma of the lower genital tract. Additional investigations, preferably involving prospective studies, are warranted to confirm our findings. It is recommended that rigorous gynecologic exams with Pap smears and imaging analyses be performed periodically in women with genital malformations, especially in those with simultaneous urinary malformations, as they may be at risk of developing genital malignancies.
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AC

:   adenocarcinoma

ASC

:   adenosquamous carcinoma

BSO

:   bilateral salpingo-oophorectomy

CCA

:   clear cell adenocarcinoma

CCRT

:   concomitant chemoradiotherapy

CIN

:   cervical intraepithelial neoplasia

CIS

:   carcinoma in situ

DDP

:   cis-dichlorodiammine platinum

DES

:   diethylstilbestrol

DOD

:   died of disease

EAC

:   endometrioid adenocarcinoma

HPV

:   Human papillomavirus

HWWS

:   Herlyn-Werner-Wunderlich Syndrome

LSO

:   left salpingo-oophorectomy

MA

:   mesonephric adenocarcinoma

MRKH syndrome

:   Mayer-Rokitansky-Kuster-Hauser syndrome

MRH

:   modified radical hysterectomy

MRI

:   magnetic resonance imaging

NA

:   not available

NED

:   no evidence of disease

OHVIRA

:   obstructed hemivagina and ipsilateral renal anomaly

PE

:   pelvic exenteration

PF

:   platinum plus 5-fluorouracil

PLA

:   Pelvic lymphadenectomy

PPLA

:   pelvic-paraaortic lymphadenectomy

PUMCH

:   Peking Union Medical College Hospital

PV

:   partial vaginectomy

SCC

:   squamous-cell carcinoma

RH

:   radical hysterectomy

RSO

:   right salpingo-oophorectomy

TC

:   paclitaxel plus carboplatin

TP

:   pacitaxel plus platinum

TV

:   total vaginectomy

UD

:   uterus didelphys

URA

:   unilateral renal agenesis

VB

:   vaginal bleeding

![The representative radiological and pathological images in patients with lower genital tract carcinomas and genitourinary malformation treated at the Peking Union Medical College Hospital. A. T1-weighted magnetic resonance imaging (patient 8). A uterine cervical tumor was detected on both sides of the uterine cervix. B. Surgically resected tissues of a patient with Herlyn-Werner-Wunderlich syndrome (patient 6). C. Histopathological findings of a specimen showing clear cell adenocarcinoma of the vagina (hematoxylin-eosin staining, ×200). D. Histopathological findings of a specimen showing clear cell adenocarcinoma of the cervix (hematoxylin-eosin staining, ×100)](jcav10p3054g001){#F1}

###### 

Clinical features in 12 patients with genital tract carcinomas and malformation treated at the PUMCH

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.   Age   Site & Stage                       Histology   Genitourinary malformation                                                                    Initial treatment                                               Course and further treatment                                                                                            Follow up   
  ----- ----- ---------------------------------- ----------- --------------------------------------------------------------------------------------------- --------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- ----------- -------------------
  1     36    Cervix ⅡB                          AC          URA, UD                                                                                       Radiotherapy, TAH+BSO, chemotherapy (TC\*6)                     Local recurrence and distant metastases at 3 yr., chemotherapy (TP\*6), radiotherapy, distant metastases at 5^th^ yr.   7 yr.       DOD

  2     53    Vagina Ⅱ                           AC          URA, UD                                                                                       CCRT ( no response), PE                                         Distant metastases at 1.5 yr.                                                                                           2.5 yr.     Alive with cancer

  3     20    Vagina, right cervix Ⅰ             CCA         HWWS (URA)                                                                                    LRH+BSO+PLA+TV                                                  Uneventful                                                                                                              3 yr.       NED

  4     27    Vagina, right cervix ⅡB            AC          HWWS (URA)                                                                                    CCRT, LH+BSO+ TV, chemotherapy (TC\*6)                          Local recurrence and kidney failure after 1 yr.                                                                         2 yr.       DOD

  5     44    Vagina Ⅱ                           AC          URA, bicornuate uterus, vaginal septum                                                        CCRT (TC\*6) and interstitial brachytherapy                     Uneventful                                                                                                              1 yr.       NED

  6     31    Double cervix, vaginal septum ⅡA   CCA         HWWS (URA)                                                                                    Chemotherapy (TP\*3), LH+BSO+PPLA, chemotherapy (TP\*2), CCRT   Local recurrence and distant metastases after 4 months, chemotherapy (TC\*3) and PE                                     1.5 yr.     DOD

  7     38    Cervix ⅡA                          AC          HWWS (URA)                                                                                    RH+BSO+PPLA, radiotherapy                                       Distant metastases after 1 year                                                                                         2 yr.       DOD

  8     26    Double cervix\                     CCA         UD, double cervix, double vagina, vaginal atresia, vagino-vesical fistula, imperforate anus   LSO, chemotherapy (TP\*3, PF\*2), radiotherapy, PE              Uneventful                                                                                                              1 yr.       NED
              IVa                                                                                                                                                                                                                                                                                                                                              

  9     26    Vagina Ⅰ                           CCA         microperforate hymen, multiple renal cysts                                                    chemotherapy (PF\*5), PV, CCRT                                  Uneventful                                                                                                              3 yr.       NED

  10    52    Cervix ⅡB                          SCC         septate uterus                                                                                CCRT                                                            Distant metastases after 14 months, chemotherapy (TC\*5)                                                                1 yr.       Alive with cancer

  11    61    Cervix IA1                         SCC         UD                                                                                            LH+BSO                                                          Uneventful                                                                                                              1.5 yr.     NED

  12    43    Cervix IB1                         SCC         UD                                                                                            LH+BSO+PLN, CCRT                                                Uneventful                                                                                                              10 yr.      NED
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: AC, adenocarcinoma; CCA, clear cell adenocarcinoma; CCRT, concomitant chemoradiotherapy; CIN, cervical intraepithelial neoplasia; DDP, cis-Dichlorodiammine platinum; DOD, died of disease; HWWS, Herlyn-Werner-Wunderlich Syndrome; LSO, left salpingo-oophorectomy; NED, no evidence of disease; PE, pelvic exenteration; PF, platinum plus 5-fluorouracil; PV, partial vaginectomy; SCC, squamous-cell carcinoma; TC, paclitaxel plus carboplatin; TP, pacitaxel plus platinum; TV, total vaginectomy; UD, uterus didelphys; URA, unilateral renal agenesis.

###### 

Clinical features in 24 patients with genital tract carcinomas and malformations identified from literature

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors                Age   Site & Stage                       Histology   genito-urinary malformation                             Treatment                                                                   Follow up   outcome
  ---------------------- ----- ---------------------------------- ----------- ------------------------------------------------------- --------------------------------------------------------------------------- ----------- ---------
  Plesinac-Karapandzic   25    Vagina Ⅱ                           AC          URA                                                     Radiotherapy                                                                15 yr.      NED

  Plesinac-Karapandzic   20    Vagina Ⅲ                           MA          URA                                                     Chemotherapy and radiotherapy                                               11 yr.      NED

  Cordoba                37    Left cervix IIIA                   AC          HWWS (URA)                                              aortic lymphadenectomy + CCRT                                               30 Mos.     NED

  Platta                 34    Cervix IIB                         AC          Septate uterus                                          CCRT                                                                        20 Mos.     NED

  Kawano                 33    Right cervix IB1                   CCA         Bicornuate uterus, double cervix, URA                   MRH+RSO+PLA; radiation and chemotherapy                                     10 yr.      NED

  Kaba                   49    Right cervix IB1                   EAC         HWWS (URA)                                              RH+BSO+PPLA+omentectomy; radical parametrectomy and proximal vaginectomy    15 Mos.     NED

  Watanabe               33    Right cervix, vaginal septum IVa   EAC         HWWS (URA)                                              Chemotherapy (TC) + external radiation; anterior pelvic exenteration + TV   NA          NA

  Watanabe               53    Vagina Ⅰ                           CCA         HWWS (URA)                                              RH                                                                          NA          NA

  Talia                  41    Vagina Ⅰ                           AC          URA, double cervix and bicornuate uterus                Hysterectomy, vaginal mass resection and right PLA                          2 Mos.      NED

  Uehara                 54    Vagina Ⅰ                           CCA         Bicornuate uterus, URA, vaginal septum                  anterior pelvic exenteration                                                43 Mos.     NED

  Zeeshanuddin           27    Left vagina Ⅰ                      CCA         UD, double cervix, double vagina, URA, situs inversus   RH+ PLA+ PV, PE after recurrence                                            NA          NA

  Tewari                 34    Vagina Ⅰ                           EAC         MRKH syndrome                                           BSO+ PLA, pelvic radiotherapy                                               18 Mos.     NED

  Sporri                 49    Left cervix IIA                    CCA         Bicornuate uterus, double cervix , URA                  RH+ BSO+ PLA, pelvic radiation and vaginal irradiation                      4.5 yr.     NED

  GomezIrizarry          44    Left cervix IB\                    ASC         UD, double cervix, double vagina                        RH+ BSO+ PPLA+ omentectomy; CCRT                                            26 Mos.     DOD
                               Ovaries mets.                                                                                                                                                                                  

  Sugimori               44    Two cervices IIB                   AC          UD, vaginal septum, double cervix                       RH+ PLA + radiation                                                         NA          NA

  Nordqvist              34    Cervix IIA                         CCA         UD, double vagina, URA                                  RH+PV +PLA                                                                  24 yr.      NED

  Nordqvist              27    Cervix IB                          CCA         UD, double vagina, URA                                  RH, Intracavitary+ pelvic radiation.                                        16 yr.      NED

  Loo                    45    Two cervices IB1                   SCC         UD, double cervix                                       CCRT                                                                        2 yr.       NED

  Lee                    45    Two cervices IB1                   SCC         UD, double cervix                                       Radical radiotherapy                                                        3 yr.       NED

  Bakri                  29    Two cervices                       CIS         UD, double cervix                                       Cone                                                                        2 yr.       NED

  Tam                    69    Two cervices IB1                   SCC         UD, double cervix, vaginal septum                       RH + partial resection of vaginal septum, radiotherapy                      NA          NA

  Fox                    30    Two cervices IA                    SCC         UD, double cervix                                       Hysterectomy                                                                NA          NA

  Corbett                56    Right cervix IB1                   SCC         UD, double cervix, vaginal septum                       Radiotherapy, extended hysterectomy+ PLA                                    2 yr.       NED

  Gerbie                 40    Cervix IB                          SCC         URA, UD, rudimentary uterus                             RH +PLA                                                                     NA          NA
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: AC, adenocarcinoma; ASC, adenosquamous carcinoma; BSO, bilateral salpingo-oophorectomy; CCA, clear cell adenocarcinoma; CCRT, concomitant chemoradiotherapy; CIS, carcinoma in situ; DOD, died of disease; EAC, endometrioid adenocarcinoma; HWWS, Herlyn-Werner-Wunderlich syndrome; MA, mesonephric adenocarcinoma; MRKH syndrome, Mayer-Rokitansky-Kuster-Hauser syndrome; MRH, modified radical hysterectomy; NED, No evidence of disease; NA, not available; PE, pelvic exenteration; PLA, Pelvic lymphadenectomy; PPLA, pelvic-paraaortic lymphadenectomy; PV, partial vaginectomy; RH, radical hysterectomy; RSO, right salpingo-oophorectomy; TC, paclitaxel and carboplatin; UD, uterus didelphys; URA, unilateral renal agenesis.

###### 

Clinicopathologic characteristics of 36 patients with genital malformations who developed carcinomas

  Variables                                        Category             N    \%
  ------------------------------------------------ -------------------- ---- ------
  Parity (n=30)                                    0                    10   33.3
                                                   1                    8    26.7
                                                   ≥2                   12   40.0
  Symptoms (n=31)                                  Postcoital VB        4    12.9
                                                   Vaginal discharge    3    9.7
                                                   Intermenstrual VB    17   54.8
                                                   Periodic hematuria   1    3.2
                                                   Abnormal Pap smear   3    9.7
                                                   Postmenopausal VB    3    9.7
  Sites of carcinoma                               Cervix               22   61.1
                                                   Vagina               10   27.8
                                                   Cervix and vagina    4    11.1
  \*FIGO stage of cervical carcinoma (n=25)        Ⅰ                    13   52.0
                                                   Ⅱ                    9    36.0
                                                   Ⅲ                    1    4.0
                                                   Ⅳ                    2    8.0
  FIGO stage of vaginal carcinoma (n=10)           Ⅰ                    6    60.0
                                                   Ⅱ                    3    30.0
                                                   Ⅲ                    1    10.0
  Pathology of cervix and vagina                   Adenocarcinoma       25   69.4
                                                   SCC                  10   27.8
                                                   ASC                  1    2.8
  Urinary tract malformation                       URA                  21   58.3
                                                   Others               2    5.6
                                                   No malformation      13   36.1
  Genital tract malformation                       HWWS                 8    22.2
                                                   Uterus didelphys     17   47.2
                                                   Others               11   30.6
  Sites of carcinoma in patients with 2 cervices   One cervix           9    45.0
  (n=20)                                           Two cervices         8    40.0
                                                   Vagina (no cervix)   3    15.0

\*1 carcinoma in situ was not included

Abbreviations: ASC, adenosquamous carcinoma; HWWS, Herlyn-Werner-Wunderlich syndrome; PUMCH, Peking Union Medical College Hospital; SCC, squamous-cell carcinoma; URA, unilateral renal agenesis; VB, vaginal bleeding

###### 

Correlation between clinical variables and pathology in patients with genital malformations who developed carcinomas

  Variables                    Pathology   *P*      
  ---------------------------- ----------- -------- ---------
                               SCC         AC/ASC   
  Age (years)                  47.0        36.1     0.011
  Urinary tract malformation                        \<0.001
  Yes                          1           22       
  No                           9           4        
  Stage                                             0.022
  Ⅰ                            9           11       
  Ⅱ-Ⅳ                          1           15       
  Site of carcinoma                                 0.003
  Cervix                       12          10       
  Vagina with/without cervix   0           14       

Abbreviations: AC, adenocarcinoma; ASC, adenosquamous carcinoma; SCC, squamous-cell carcinoma
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